Hypoxia also contributes to the invasive and metastatic phenotypes of aggressive cancers by promoting genetic instability and accelerating the accumulation of mutations that can ultimately give rise to drug resistance.
There are several companies developing HAPs: Novacea, Inc., Proacta Inc. and Threshold Pharmaceuticals, Inc. These companies are developing the following drug candidates: AQ4N (Novacea), PR-104 (Proacta) and TH-302 (Threshold Pharmaceuticals).
WIPO PUBLISHES PATENT OF THRESHOLD PHARMACEUTICALS FOR "ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER" (AMERICAN INVENTORS)
Jan 24, 2012; GENEVA, Jan. 24 -- Publication No. WO/2012/009288 was published on Jan. 19. Title of the invention: "ADMINISTRATION OF HYPOXIA...